Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.
Press releases published on August 14, 2025
Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das bereit für die klinische Phase-3-Entwicklung ist
GlobeNewswire
·
August 14, 2025
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 14. August 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch …
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
GlobeNewswire
·
August 14, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal …
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
GlobeNewswire
·
August 14, 2025
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores …
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
GlobeNewswire
·
August 14, 2025
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025 …
Kuros Biosciences Reports First Half of 2025 Results
GlobeNewswire
·
August 14, 2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ …
Zealand Pharma Announces Financial Results for the First Half of 2025
GlobeNewswire
·
August 14, 2025
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next …
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering
GlobeNewswire
·
August 14, 2025
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced …